Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $53.00 price target on Kymera Therapeutics (NASDAQ: KYMR) following Q1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Kymera Therapeutics (KYMR) Tops Q1 EPS by 7cMay 9, 2025 7:21 AM Form 10-Q Kymera Therapeutics, For: Mar 31May 9, 2025 7:16 AM Form 8-K Kymera Therapeutics, For: May 09May 9, 2025 7:05 AM Kymera Therapeutics (KYMR) Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory DiseasesMay 9, 2025 7:04 AM